

# Richard Ceska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3612579/publications.pdf>

Version: 2024-02-01

113  
papers

7,537  
citations

147786

31  
h-index

51602

86  
g-index

141  
all docs

141  
docs citations

141  
times ranked

7541  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499.	27.0	1,838
2	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 370, 1809-1819.	27.0	607
3	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870.	7.4	422
4	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1580.	7.4	420
5	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015, 36, ehv370.	2.2	395
6	Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1232-1238.	8.6	372
7	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	1.6	371
8	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	311
9	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. <i>Journal of Clinical Investigation</i> , 2000, 106, 1263-1270.	8.2	295
10	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	2.0	227
11	Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. <i>PLoS ONE</i> , 2012, 7, e49006.	2.5	190
12	Editorial. <i>American Journal of Cardiology</i> , 1998, 81, 912-917.	1.6	187
13	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial – FAT). <i>Cardiovascular Research</i> , 2001, 52, 290-298.	3.8	131
14	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	2.4	117
15	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
16	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 455-463.	11.4	84
17	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
18	Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. <i>Psychiatry Research</i> , 2005, 133, 197-203.	3.3	78

#	ARTICLE	IF	CITATIONS
19	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020, 5, 709.	6.1	63
20	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. <i>Nutrition</i> , 2001, 17, 721-723.	2.4	57
21	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002, 144, E6.	2.7	56
22	Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles heel?. <i>Current Medical Research and Opinion</i> , 2011, 27, 1551-1562.	1.9	55
23	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. <i>Annals of Medicine</i> , 2010, 42, 447-464.	3.8	49
24	T-1131 polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. <i>Atherosclerosis</i> , 2003, 167, 369-370.	0.8	48
25	Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management. <i>Physiological Research</i> , 2014, 63, S327-S334.	0.9	45
26	Statin Intolerance: the Clinician's Perspective. <i>Current Atherosclerosis Reports</i> , 2015, 17, 69.	4.8	43
27	Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1088-1092.	3.4	42
28	FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention. <i>Clinical Biochemistry</i> , 2013, 46, 313-316.	1.9	39
29	Impact of apolipoprotein A5 variants on statin treatment efficacy. <i>Pharmacogenomics</i> , 2009, 10, 945-950.	1.3	38
30	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. <i>European Journal of Pharmacology</i> , 2004, 493, 183-189.	3.5	35
31	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.3	35
32	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	1.8	32
33	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. <i>American Journal of Cardiology</i> , 2003, 92, 337-341.	1.6	31
34	MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. <i>Human Genetics</i> , 2008, 124, 553-555.	3.8	28
35	Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolemia or mixed dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2010, 64, 727-738.	1.7	27
36	Serum leptin levels in patients with hyperlipidemias. <i>Nutrition</i> , 2000, 16, 429-433.	2.4	26

#	ARTICLE	IF	CITATIONS
37	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. <i>American Heart Journal</i> , 2003, 146, 1060-1063.	2.7	26
38	Ser19->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. <i>Journal of Medical Genetics</i> , 2003, 40, 105e-105.	3.2	25
39	SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population. <i>Medical Science Monitor</i> , 2015, 21, 1454-1459.	1.1	24
40	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. <i>American Heart Journal</i> , 2003, 146, 110A-115A.	2.7	22
41	Treatment of Hypertriglyceridemia: a Review of Current Options. <i>Physiological Research</i> , 2015, 64, S331-S340.	0.9	22
42	Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project. <i>Physiological Research</i> , 2017, 66, S1-S9.	0.9	21
43	Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. <i>Physiological Research</i> , 2003, 52, 439-45.	0.9	21
44	Impact of Variants Within Seven Candidate Genes on Statin Treatment Efficacy. <i>Physiological Research</i> , 2012, 61, 609-617.	0.9	20
45	Clinical implications of the metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S2-S4.	2.0	18
46	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.1	17
47	Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR $\alpha$ Modulator, in European Patients on Statin Therapy. <i>Diabetes Care</i> , 2022, 45, 898-908.	8.6	17
48	Ivabradine in Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2435-2435.	27.0	16
49	Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. <i>Clinica Chimica Acta</i> , 2016, 454, 119-123.	1.1	15
50	Hypertriglyceridemia: Interaction between APOE and APOAV Variants. <i>Clinical Chemistry</i> , 2005, 51, 1311-1313.	3.2	14
51	Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. <i>Clinica Chimica Acta</i> , 2007, 376, 77-81.	1.1	13
52	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. <i>Current Atherosclerosis Reports</i> , 2019, 21, 36.	4.8	13
53	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 773-7.	2.3	12
54	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002, 144, G1-G8.	2.7	11

#	ARTICLE	IF	CITATIONS
55	Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. <i>European Journal of Internal Medicine</i> , 2015, 26, 367-368.	2.2	11
56	The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Caseâ€“Control Study. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 555-562.	3.8	10
57	The Impact of Physical Activity and Dietary Measures on the Biochemical and Anthropometric Parameters in Obese Children. Is There Any Genetic Predisposition?. <i>Central European Journal of Public Health</i> , 2015, 23, S62-S66.	1.1	10
58	Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. <i>Physiological Research</i> , 2008, 57, 919-925.	0.9	10
59	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. <i>Archives of Medical Science</i> , 2017, 4, 705-710.	0.9	9
60	ApoE genotype is not associated with variations in bone mineral density. <i>Atherosclerosis</i> , 1999, 144, 103-104.	0.8	8
61	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <i>Atherosclerosis</i> , 2003, 166, 195-196.	0.8	8
62	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2003, 166, 197-198.	0.8	8
63	Nitroglycerin Induced Syncope Occurs in Subjects with Delayed Phase Shift of Baroreflex Action. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 828-832.	1.2	7
64	Increase of inflammatory state in overweight adults with combined hyperlipidemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003, 13, 227-231.	2.6	7
65	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2005, 183, 367-368.	0.8	7
66	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. <i>Cor Et Vasa</i> , 2014, 56, e133-e139.	0.1	7
67	Body Adiposity Changes After Lifestyle Interventions in Children/Adolescents and the NYD-SP18 and TMEM18 Variants. <i>Medical Science Monitor</i> , 2018, 24, 7493-7498.	1.1	7
68	Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report 1. <i>Journal of Internal Medicine</i> , 1999, 246, 235-236.	6.0	6
69	The apo(a) gene (TTTTA) <sub>n</sub> promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10. <i>Clinica Chimica Acta</i> , 2009, 405, 39-42.	1.1	6
70	Rosiglitazone Influences the Expression of Leukocyte Adhesion Molecules and CD14 Receptor in Type 2 Diabetes Mellitus Patients. <i>Physiological Research</i> , 2014, 63, S293-S298.	0.9	6
71	ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS. <i>Physiological Research</i> , 2017, 66, S85-S90.	0.9	6
72	Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction. <i>Experimental and Clinical Cardiology</i> , 2003, 8, 151-4.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. <i>Neuroendocrinology Letters</i> , 2012, 33 Suppl 2, 22-5.	0.2	6
74	PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology. <i>Current Atherosclerosis Reports</i> , 2022, , 1.	4.8	6
75	Decreasing Common Carotid Artery Intimal Thickness During Hypolipidemic Therapy. <i>Angiology</i> , 1997, 48, 761-767.	1.8	5
76	Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2000, 89, 1023-1024.	1.5	5
77	Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels. <i>Clinical Biochemistry</i> , 2010, 43, 754-758.	1.9	4
78	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. <i>Clinica Chimica Acta</i> , 2011, 412, 920-924.	1.1	4
79	Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. <i>Journal of Applied Biomedicine</i> , 2012, 10, 19-28.	1.7	4
80	APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, e22-e23.	2.6	4
81	Statins, Glycemia, and Diabetes Mellitus: Another Point of View. <i>Current Atherosclerosis Reports</i> , 2014, 16, 458.	4.8	4
82	Statin Intolerance in Clinical Practice. <i>Current Atherosclerosis Reports</i> , 2020, 22, 27.	4.8	4
83	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. <i>Frontiers in Genetics</i> , 2022, 13, 849008.	2.3	4
84	Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels. <i>Clinical Biochemistry</i> , 2007, 40, 802-805.	1.9	3
85	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. <i>International Congress Series</i> , 2004, 1262, 458-461.	0.2	2
86	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. <i>Medical Hypotheses</i> , 2008, 70, 199-200.	1.5	2
87	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. <i>Atherosclerosis Supplements</i> , 2008, 9, 40.	1.2	2
88	Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal. <i>Current Atherosclerosis Reports</i> , 2014, 16, 463.	4.8	2
89	Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes. <i>Folia Biologica</i> , 2019, 65, 188-194.	0.6	2
90	Flow-Dependent Vasomotor Dysfunction of the Popliteal Artery Related to Common Carotid Artery Intima-Media Thickness. <i>Angiology</i> , 2001, 52, 689-695.	1.8	1

#	ARTICLE	IF	CITATIONS
91	T06-P-019 Apolipoprotein E gene polymorphism in the Mongolian population. <i>Atherosclerosis Supplements</i> , 2005, 6, 169.	1.2	1
92	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. <i>Nutrition Research</i> , 2007, 27, 181-185.	2.9	1
93	Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145. <i>European Heart Journal</i> , 2013, 34, P681-P681.	2.2	1
94	Fifteen years of active search for patients with familial hypercholesterolemia in the Czech Republic. <i>Atherosclerosis</i> , 2014, 235, e197.	0.8	1
95	Effect of APOE genotype on LDL cholesterol levels in FH and FDB patients: Is there sex-specifically protective genotype?. <i>Atherosclerosis</i> , 2016, 252, e40.	0.8	1
96	Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. <i>Current Pharmaceutical Design</i> , 2015, 21, 1180-1184.	1.9	1
97	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 Years. Part II. Clinical Characteristics. <i>Frontiers in Genetics</i> , 2022, 13, 849267.	2.3	1
98	1.P.161 The effect of stain therapy on common carotid artery intimal thickness in patients with familial hyperlipidemia. <i>Atherosclerosis</i> , 1997, 134, 50.	0.8	0
99	2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients. <i>Atherosclerosis</i> , 1997, 134, 110-111.	0.8	0
100	Apolipoprotein E polymorphism in patients with different types of hyperlipidemia. <i>Atherosclerosis</i> , 1999, 144, 21.	0.8	0
101	Type III hyperlipoproteinaemia in patient with severe hypothyroidism accompanied by primary amenorrhoea. <i>Atherosclerosis</i> , 1999, 144, 158.	0.8	0
102	Use of the D19S394 tetranucleotide repeat in the diagnosis of familial hypercholesterolemia. <i>Atherosclerosis</i> , 1999, 144, 195-196.	0.8	0
103	The independent correlation of the impact of lipoprotein(a) levels and apolipoprotein E polymorphism on carotid artery intima thickness. <i>Atherosclerosis</i> , 2000, 151, 311.	0.8	0
104	New Strategies in the Treatment of Dyslipidemia: Do We Know How?. <i>Seminars in Vascular Medicine</i> , 2004, 4, 305-310.	2.1	0
105	W15-P-006 Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2005, 6, 98.	1.2	0
106	Mo-P6:430 Lipoprotein (A), its relation to gene control regions. <i>Atherosclerosis Supplements</i> , 2006, 7, 140-141.	1.2	0
107	We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2006, 7, 371.	1.2	0
108	Is it safe to combine PPAR agonists? A lesson from muraglitazar. <i>Medical Hypotheses</i> , 2006, 67, 669.	1.5	0

#	ARTICLE	IF	CITATIONS
109	PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES. <i>Atherosclerosis Supplements</i> , 2007, 8, 69.	1.2	0
110	SLCO1B1 transporter polymorphism is not associated with risk of myopathy in Czech population. <i>Atherosclerosis</i> , 2014, 235, e256.	0.8	0
111	Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study. <i>Atherosclerosis</i> , 2014, 235, e12.	0.8	0
112	FH homozygote without cardiovascular disease at the age of 40. <i>Atherosclerosis</i> , 2015, 241, e112.	0.8	0
113	Comments on the most important and recent studies involving PCSK9i. <i>Vnitřní Lékarství</i> , 2018, 64, 1137-1141.	0.2	0